# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001171843-26-002720
Filing Date
2026-04-27
Accepted
2026-04-27 07:30:23
Documents
30
Period of Report
2026-04-27
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | FORM 8-K | f8k_042526.htm iXBRL | 8-K | 27121
2 | PRESS RELEASE | exh_991.htm | EX-99.1 | 15378
3 | EXHIBIT 99.2 | exh_992.htm | EX-99.2 | 21106
4 |  | exh992_01.jpg | GRAPHIC | 185412
5 |  | exh992_02.jpg | GRAPHIC | 252285
6 |  | exh992_03.jpg | GRAPHIC | 166649
7 |  | exh992_04.jpg | GRAPHIC | 151851
8 |  | exh992_05.jpg | GRAPHIC | 126193
9 |  | exh992_06.jpg | GRAPHIC | 206995
10 |  | exh992_07.jpg | GRAPHIC | 103406
11 |  | exh992_08.jpg | GRAPHIC | 120541
12 |  | exh992_09.jpg | GRAPHIC | 114448
13 |  | exh992_10.jpg | GRAPHIC | 98321
14 |  | exh992_11.jpg | GRAPHIC | 103928
15 |  | exh992_12.jpg | GRAPHIC | 103602
16 |  | exh992_13.jpg | GRAPHIC | 194441
17 |  | exh992_14.jpg | GRAPHIC | 187426
18 |  | exh992_15.jpg | GRAPHIC | 164033
19 |  | exh992_16.jpg | GRAPHIC | 80784
| Complete submission text file | 0001171843-26-002720.txt |  | 3527465

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
20 | XBRL SCHEMA FILE | gnw-20250101.xsd | EX-101.SCH | 3402
21 | XBRL DEFINITION FILE | gnw-20250101_def.xml | EX-101.DEF | 26066
22 | XBRL LABEL FILE | gnw-20250101_lab.xml | EX-101.LAB | 35956
23 | XBRL PRESENTATION FILE | gnw-20250101_pre.xml | EX-101.PRE | 24702
33 | EXTRACTED XBRL INSTANCE DOCUMENT | f8k_042526_htm.xml | XML | 2849

Mailing Address 80 GUEST STREET BOSTON MA 02135
Business Address 80 GUEST STREET BOSTON MA 02135 617-500-8099
Compass Therapeutics, Inc. (Filer) CIK: 0001738021 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39696 | Film No.: 26896533
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)